A woman in a checkered jumper having chemotherapy

BOUQUET: A trial of different biomarker driven drugs in platinum-resistant ovarian cancer

Trial at a glance

Open trial

  • Cancer type: Epithelial – mucinous | Epithelial – low-grade serous | Rarer ovarian tumours
  • Treatment stage: Recurrence
  • Acronym: BOUQUET

BOUQUET: A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors

Who can take part

Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.


You may be able to take part in this trial if you:

  • are 18 years old or over
  • have one of the following rarer types of ovarian, fallopian tube or primary peritoneal cancer
    • low-grade serous ovarian carcinoma
    • clear cell carcinoma
    • mucinous carcinoma
    • carcinosarcoma
    • undifferentiated carcinoma
    • seromucinous carcinoma
    • malignant Brenner tumours
    • grades 1 or 2 endometrioid carcinoma or
    • small cell carcinoma of the ovary-hypercalcemic type
  • have received at least one previous treatment for your disease including at least one platinum-based treatment
  • your cancer is considered platinum-resistant

This is not an exhaustive list. If you're interested in participating in a clinical trial, you should speak to your doctor about what other criteria might apply.

About the trial

The researchers in this clinical trial want to test the safety and effectiveness of different type of anti-cancer treatments in patients with different genetic changes (biomarkers) in their cancer. The trial is for women with rarer types of ovarian cancer where standard chemotherapy drugs haven't worked.

The drugs involved in this clinical trial are:

  • ipatasertib – an AKT inhibitor (a tablet taken by mouth).
  • paclitaxel – a standard chemotherapy drug (given as a drip into the vein).
  • cobimetinib – a mitogen-activated protein kinase (MAPK) inhibitor (a tablet taken by mouth).
  • trastuzumab emtansine – a monoclonal antibody combined with a chemotherapy drug (given as a drip into the vein). 
  • atezolizumab – a type of immunotherapy drug (given as a drip into the vein).
  • bevacizumab – an anti-angiogenesis drug (given as a drip into the vein).

Everyone who joins this clinical trial will have tests to look for biomarkers in their cancer (biomarker screening). The tests are performed on a small tissue sample taken from the tumour.

If you take part in this study, you'll be placed into one of four groups depending on the biomarkers found. This will determine which treatment you'll be given:

  • Group one: those with changes in the PTEN, PIK3CA and/or AKT1 genes will receive ipatasertib, plus paclitaxel.
  • Group two: those with changes in the BRAF, KRAS, NRAS and/or NF1 genes will receive cobimetinib.
  • Group three: those with changes in the ERBB2 gene will receive trastuzumab emtansine.
  • Group four: those with none of the above changes will receive atezolizumab plus bevacizumab.

You'll be given the clinical trial treatment for as long as it can help you. You're free to stop this treatment at any time. 

After finishing your treatment, you'll have regular checkups with the research team.